Prognose
Vi har ingen analytikerdata for denne virksomhed.
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Kuros Biosciences share: CHF 10,000 investment a year ago now 13.47% down
If CHF 10,000 had been invested in Kuros Biosciences a year ago (closing price then 26.58 CHF), that would equal 376.223 shares at the last closing price of 23.00 CHF, worth CHF 8,653.12 today. That corresponds to a decline of 13.47 percent. Market capitalization most recently stood at CHF 914.34 million; calculation does not take stock splits or dividends into account. » Mere på finanzen.net
Kuros confirms full-year targets after strong first half
Kuros reports a strong H1 2026: revenue rose 45% to $92.4 million and adjusted EBITDA increased 61% to $12.5 million, with the margin improving to 13.6%. The company posted a first-time net profit of $4.4 million after a loss in the prior year. Kuros reiterates its full-year targets of at least 35% revenue growth and an adjusted EBITDA margin of around 14%, and it confirms its mid-term 2028 target (revenue $300–330 million, adjusted EBITDA margin ≥20%). To support growth, Kuros is advancing product development, market expansion and production capacity in the US and the Netherlands. » Mere på finanzen.net
Kuros (Kuros Biosciences) stock: 10,000 CHF investment three years ago would have risen 876.08%
Three years ago the Kuros (Kuros Biosciences) stock traded at 2.09 CHF. A 10,000 CHF investment would be worth 97,607.66 CHF today at a closing price of 20.40 CHF, an increase of 876.08%. Market capitalization most recently stood at 786.78 million CHF; stock splits and dividends were not included in the calculation. » Mere på finanzen.net
Kuros appoints I.V. Hall as COO effective 1 June 2026
Kuros has appointed Harry Thomas Hall (I.V. Hall) as chief operating officer, effective 1 June 2026. The company thereby announces a personnel change in its executive management. » Mere på finanzen.net
Kuros Biosciences appoints I.V. Hall as chief operating officer
Kuros Biosciences appoints I.V. Hall as chief operating officer effective June 1, 2026; Sjoerd Musters will remain in office until August 1, 2026 to hand over duties. Hall brings more than 30 years of medtech experience, including 27 years at DePuy Synthes and most recently serving as CEO of Next Science. Management emphasizes strengthening the operational infrastructure and product development as Kuros advances its commercialization; revenue recently rose 72% to 146 million USD with a gross margin of 87% and a market capitalization of around 1 billion USD. » Mere på de.investing.com
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalI 2022 har Kuros Biosciences allerede udloddet 0,15 € i udbytte. Den seneste udlodning fandt sted i april 2022.
Virksomhedstal
I det seneste kvartal havde Kuros Biosciences en omsætning på 78,73 mio. € og et nettoresultat på 3,76 mio. €
| (EUR) | juni 2026 | YoY |
|---|---|---|
| Omsætning | 78,73 mio. | - |
| Bruttofortjeneste | 67,08 mio. | - |
| Nettoresultat | 3,76 mio. | - |
| EBITDA | 6,32 mio. | - |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 811,45 mio. € |
Antal aktier | 39,83 mio. |
Højeste/laveste i 52 uger | 35,25 € - 17,86 € |
| Udbytte | Nej |
Beta | 0,76 |
P/E (PE Ratio) | 103,76 |
PEG (PEG Ratio) | 0,12 |
K/I (PB Ratio) | 10,29 |
P/S (PS Ratio) | 5,38 |
Virksomhedsprofil
Kuros Biosciences AG er et biofarmaceutisk selskab, der beskæftiger sig med kommercialisering og udvikling af biofarmaceutiske produkter til vævsreparation og knogleregenerering i USA, EU og internationalt. Selskabet opererer gennem segmenterne Medical Devices, Pharmaceuticals og Legacy Portfolio. Selskabets orthobiologics-pipelineprodukter omfatter MagnetOs Granules og MagnetOs Putty i EU og USA til behandling af ortopædiske, spinale og dentale problemer. Dets fibrin/PTH-orthobiologics-pipelineprodukter omfatter KUR-111, som har gennemført et Phase 2b-klinisk forsøg til behandling af tibiaplateaufrakturer, og KUR-113, som har gennemført et Phase 2b-klinisk forsøg til behandling af tibiaskaftfrakturer, samt er i Fase II-forsøg til behandling af spinal interbody fusion. Selskabets pipelineprodukter inden for forsegling omfatter Neuroseal EU og USA, en syntetisk vævsforsegling til forebyggelse af lækage af cerebrospinalvæske efter kranie- eller rygkirurgi. Selskabet har et samarbejde med Checkmate Pharmaceuticals LLC om udvikling af CYT003 til behandling af onkologi. Selskabet har hovedkontor i Schlieren, Schweiz.
| Navn | Kuros Biosciences |
| CEO | Christopher T. Fair |
| Hjemsted | Schlieren,
zh Schweiz |
| Websted | |
| Sektor | Sundhed |
| Branche | Bioteknologi |
| Børsnotering | 03.06.2021 |
| Medarbejdere | 178 |
Tickersymboler
| Børs | Symbol |
|---|---|
SIX | KURN.SW |
London Stock Exchange | 0RHR.L |
Pnk | CSBTF |
London | 0RHR.L |
München | YTSN.MU |